RxDoctor Payments Data

Lan Su, MD

Hospitalist · Morristown, NJNPI 1093128191

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 80 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Novartis at 43.5% of the total. Reporting peaked in 2022 at $357 and has fallen 85.0% since, to $54 in 2025. Among hospitalist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,219in general payments, 2019–2025

Across 80 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$530
  • Pfizer$305
  • Merck$127
  • Johnson & Johnson$118
  • E.r. Squibb & Sons, L.L.C.$41
  • Avanir Pharmaceuticals, Inc.$41
  • plus $57 from 3 others

What the payments were for

  • Food & beverage$1,219100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,219 in reported general payments places this provider in the 90th percentile of 567 hospitalist providers in New Jersey.

See all hospitalist providers in New Jersey

Medicare billing

Part B allowed, 2024
$216,923
Medicare patients
764
Services billed
1,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban14$9,323
Metoprolol Succinate19$315
Pantoprazole Sodium38$302
Fluticasone Propionate12$203
CefuroximeCefuroxime Axetil21$184
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav25$183
Amlodipine Besylate24$128
Dexamethasone17$127
Tamsulosin Hcl12$121
Metformin Hcl ErMetformin Hcl13$88
Prednisone19$68

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$305$9,32314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 hospitalist providers in New Jersey.

Other hospitalist in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →